1
|
Fromm J, Klein A, Mentrup F, Lindner LH, Nachbichler S, Holzapfel BM, Goller SS, Knösel T, Dürr HR. Unplanned Resections of Soft Tissue Sarcomas-Necessity of Re-Resection? Cancers (Basel) 2024; 16:1851. [PMID: 38791930 PMCID: PMC11120091 DOI: 10.3390/cancers16101851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Revised: 05/08/2024] [Accepted: 05/10/2024] [Indexed: 05/26/2024] Open
Abstract
BACKGROUND In soft tissue sarcomas, unplanned resections, or so-called Whoops procedures, do occur quite frequently, thus primarily owing to the abundant presence of benign lesions. Whether re-resection reduces local recurrence or improves overall survival remains a topic of ongoing debate. The principle objective of this study was to analyze the outcomes of patients with soft tissue sarcomas of the extremities or trunk wall after an incidental marginal resection by comparing re-resections to individuals who declined the procedure. METHODS A total of 185 patients who underwent unplanned resection were included. These patients were stratified into two groups: Group A (n = 156) underwent re-excision, while Group B (n = 29) was treated conservatively. Depending on the clinical scenario, radio- or chemotherapy was either administered in a neoadjuvant or an adjuvant setting. The presence of residual tumor and metastatic disease was documented. Clinical outcomes, specifically local recurrence (LR), local recurrence-free survival (LRFS) and overall survival (OS), were utilized for evaluation. RESULTS Group B exhibited significantly larger tumors (p < 0.0001) and a higher mean age than Group A. Among the patients in Group A, 11 (5.9%) had contaminated resection margins (R1), and residual disease (RD) was observed in 93 (59.6%) of the resected specimens. In group B, 10 patients received adjuvant radiotherapy alone, 5 received chemotherapy alone, and 13 underwent a combined approach consisting of both radio- and chemotherapy. In Group A, 8% (n = 12) of the patients developed local recurrence (LR) during the observation period. Conversely, in Group B, this amount was 14% (n = 4) (n.s.). Of the 12 LR in Group A, 10 were found in the subgroup with residual disease. Overall survival and local recurrence-free survival were not significantly different between the groups. A total of 15% (n = 24) of the patients in Group A developed metastatic disease, while 10% (n = 3) in Group B developed metastatic disease (n.s.). CONCLUSIONS Following the reresection of unplanned resected STS, there was no statistically significant difference observed in overall survival or LR compared to patients who did not undergo re-resection. However, within the subgroup of patients with residual disease in the re-resected specimen, the OS was compromised, and the LR rate was higher. Particularly for low-grade lesions, adopting a more conservative approach seems to be justified.
Collapse
Affiliation(s)
- Julian Fromm
- Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (J.F.); (A.K.); (F.M.); (B.M.H.)
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
| | - Alexander Klein
- Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (J.F.); (A.K.); (F.M.); (B.M.H.)
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
| | - Franziska Mentrup
- Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (J.F.); (A.K.); (F.M.); (B.M.H.)
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
| | - Lars H. Lindner
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
- Department of Medicine III, LMU University Hospital, LMU Munich, D-81377 Munich, Germany
| | - Silke Nachbichler
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
- Department of Radiation Oncology, LMU University Hospital, LMU Munich, D-81377 Munich, Germany
| | - Boris Michael Holzapfel
- Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (J.F.); (A.K.); (F.M.); (B.M.H.)
| | - Sophia Samira Goller
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
- Department of Radiology, LMU University Hospital, LMU Munich, D-81377 Munich, Germany
| | - Thomas Knösel
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
- Institute of Pathology, LMU Munich, D-81377 Munich, Germany
| | - Hans Roland Dürr
- Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (J.F.); (A.K.); (F.M.); (B.M.H.)
- SarKUM, Center of Bone and Soft Tissue Tumors, LMU University Hospital, LMU Munich, D-81377 Munich, Germany; (L.H.L.); (S.N.); (S.S.G.); (T.K.)
| |
Collapse
|
2
|
Gouin F, Michot A, Jafari M, Honoré C, Mattei JC, Rochwerger A, Ropars M, Tzanis D, Anract P, Carrere S, Gangloff D, Ducoulombier A, Lebbe C, Guiramand J, Waast D, Marchal F, Sirveaux F, Causeret S, Gimbergues P, Fiorenza F, Paquette B, Soibinet P, Guilloit JM, Le Nail LR, Dujardin F, Brinkert D, Chemin-Airiau C, Morelle M, Meeus P, Karanian M, Le Loarer F, Vaz G, Blay JY. Improved Metastatic-Free Survival after Systematic Re-Excision Following Complete Macroscopic Unplanned Excision of Limb or Trunk Soft Tissue Sarcoma. Cancers (Basel) 2024; 16:1365. [PMID: 38611043 PMCID: PMC11010862 DOI: 10.3390/cancers16071365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 03/22/2024] [Accepted: 03/27/2024] [Indexed: 04/14/2024] Open
Abstract
BACKGROUND Whether re-excision (RE) of a soft tissue sarcoma (STS) of limb or trunk should be systematized as adjuvant care and if it would improve metastatic free survival (MFS) are still debated. The impact of resection margins after unplanned macroscopically complete excision (UE) performed out of a NETSARC reference center or after second resection was further investigated. METHODS This large nationwide series used data from patients having experienced UE outside of a reference center from 2010 to 2019, collected in a French nationwide exhaustive prospective cohort NETSARC. Patient characteristics and survival distributions in patients reexcised (RE) or not (No-RE) are reported. Multivariate Cox proportional hazard model was conducted to adjust for classical prognosis factors. Subgroup analysis were performed to identify which patients may benefit from RE. RESULTS Out of 2371 patients with UE for STS performed outside NETSARC reference centers, 1692 patients were not reviewed by multidisciplinary board before treatment decision and had a second operation documented. Among them, 913 patients experienced re-excision, and 779 were not re-excised. Characteristics were significantly different regarding patient age, tumor site, size, depth, grade and histotype in patients re-excised (RE) or not (No-RE). In univariate analysis, final R0 margins are associated with a better MFS, patients with R1 margins documented at first surgery had a better MFS as compared to patients with first R0 resection. The study identified RE as an independent favorable factor for MFS (HR 0.7, 95% CI 0.53-0.93; p = 0.013). All subgroups except older patients (>70 years) and patients with large tumors (>10 cm) had superior MFS with RE. CONCLUSIONS RE might be considered in patients with STS of limb or trunk, with UE with macroscopic complete resection performed out of a reference center, and also in originally defined R0 margin resections, to improve LRFS and MFS. Systematic RE should not be advocated for patients older than 70 years, or with tumors greater than 10 cm.
Collapse
Affiliation(s)
- Francois Gouin
- Surgery Department, Centre Léon Bérard, 69008 Lyon, France (G.V.)
| | - Audrey Michot
- Surgery Department, Institut Bergonié, 33076 Bordeaux, France
| | - Mehrdad Jafari
- General and Digestive Oncologic Surgery, Centre Oscar Lambret, 59000 Lille, France
| | - Charles Honoré
- Surgery Department, Gustave Roussy Cancer Campus, 94805 Villejuif, France
| | - Jean Camille Mattei
- Orthopedic and Traumatologic Surgery Department, Hôpital Nord, Hopital de la Conception, APHM, 13005 Marseille, France
| | - Alexandre Rochwerger
- Orthopedic and Traumatologic Surgery Department, Hôpital Nord, Hopital de la Conception, APHM, 13005 Marseille, France
| | - Mickael Ropars
- Orthopedic Surgery Department, CHU de Rennes, 35033 Rennes, France;
| | - Dimitri Tzanis
- Surgery Department, Institut Curie, PSL University, 75248 Paris, France;
| | - Philippe Anract
- Orthopedic Surgery Department, Hôpital Cochin, AP-HP, Université de Paris, Faculté de Santé, Unités de Formation et de Recherche de Médecine, 75015 Paris, France
| | - Sébastien Carrere
- Surgery Department, Institut de Recherche en Cancérologie, 34298 Montpellier, France
| | | | - Agnès Ducoulombier
- Senology Surgery Department, Onco-Gynécologique et Reconstructrice, Centre Antoine Lacassagne, 06100 Nice, France
| | - Céleste Lebbe
- Reconstructive et Esthetic Plastic Surgery, Hôpital Saint Louis, 75010 Paris, France
| | - Jérôme Guiramand
- Surgery Department, Institut Paoli Calmette, 13009 Marseille, France
| | - Denis Waast
- Orthopedic and Traumatologic Surgery Clinic, CHU Nantes, 44093 Nantes, France
| | - Frédéric Marchal
- Surgery Department, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS, CRAN, UMR 7039, 54000 Nancy, France
| | | | - Sylvain Causeret
- Surgery Department, Centre George-François Leclerc, 21079 Dijon, France;
| | - Pierre Gimbergues
- Surgery Department, Centre Jean Perrin, 63011 Clermont Ferrand, France
| | - Fabrice Fiorenza
- Orthopedic and Traumatology Surgery Department, CHU Limoges, 87000 Limoges, France
| | - Brice Paquette
- Department of Digestive Surgery, Jean Minjoz University Hospital, 25000 Besançon, France;
| | - Pauline Soibinet
- Medical Oncology Department, Institut Godinot, 51100 Reims, France
| | - Jean-Marc Guilloit
- Visceral et Digestive Surgery Department, Centre François Baclesse, 14076 Caen, France
| | - Louis R. Le Nail
- Onco-Orthopedic Surgery Department, Hôpital Trousseau, CHRU de Tours, 37000 Tours, France
| | - Franck Dujardin
- Medical Oncology and Surgical Oncology Department, Centre Henri Becquerel, 76038 Rouen, France
| | - David Brinkert
- Orthopedic Surgery Department, CHU de Strasbourg, 67200 Strasbourg, France;
| | - Claire Chemin-Airiau
- Clinical Research and Innovation Department, Centre Léon Bérard, 69008 Lyon, France
| | - Magali Morelle
- Clinical Research and Innovation Department, Centre Léon Bérard, 69008 Lyon, France
| | - Pierre Meeus
- Surgery Department, Centre Léon Bérard, 69008 Lyon, France (G.V.)
| | - Marie Karanian
- Department of Biopathology, Centre Léon Bérard, 69008 Lyon, France
| | - François Le Loarer
- Anatomo-Pathology Surgery Department, Institut Bergonié, 33076 Bordeaux, France
| | - Gualter Vaz
- Surgery Department, Centre Léon Bérard, 69008 Lyon, France (G.V.)
| | - Jean-Yves Blay
- Department of Medical Oncology, University Claude Bernard Lyon I, 69008 Lyon, France
- Department of Medicine, Léon Bérard Center, Unicancer, 69008 Lyon, France
| |
Collapse
|
3
|
Miura J, Sabharwal S, Ghert M, Karakousis G, Roland CL. Great Debate: Systematic Re-Resection After Macroscopic Complete Unplanned Excision of Soft Tissue Sarcoma. Ann Surg Oncol 2024; 31:2047-2050. [PMID: 38112886 DOI: 10.1245/s10434-023-14780-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 12/01/2023] [Indexed: 12/21/2023]
Affiliation(s)
- John Miura
- Hospital of the University of Pennsylvania, Pennsylvania, PA, USA
| | | | - Michelle Ghert
- McMaster University, Hamilton, ON, Canada
- The University of Maryland, College Park, MD, USA
| | | | | |
Collapse
|
4
|
Larios F, Gonzalez MR, Ruiz-Arellanos K, Aquilino E Silva G, Pretell-Mazzini J. Is Unplanned Excision of Soft Tissue Sarcomas Associated with Worse Oncological Outcomes?-A Systematic Review and Meta-Analysis. Cancers (Basel) 2024; 16:443. [PMID: 38275885 PMCID: PMC10814439 DOI: 10.3390/cancers16020443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 12/28/2023] [Accepted: 01/16/2024] [Indexed: 01/27/2024] Open
Abstract
BACKGROUND Soft tissue sarcomas are a group of rare neoplasms which can be mistaken for benign masses and be excised in a non-oncologic fashion (unplanned excision). Whether unplanned excision (UE) is associated with worse outcomes is highly debated due to conflicting evidence. METHODS We performed a systematic review and meta-analysis following PRISMA guidelines. Main outcomes analyzed were five-year overall survival (OS), five-year local recurrence-free survival (LRFS), amputation rate and plastic reconstruction surgery rate. Risk ratios were used to compare outcomes between patients treated with planned and unplanned excision. RESULTS We included 16,946 patients with STS, 6017 (35.5%) with UE. UE was associated with worse five-year LRFS (RR 1.35, p = 0.019). Residual tumor on the tumor bed was associated with lower five-year LRFS (RR = 2.59, p < 0.001). Local recurrence was associated with worse five-year OS (RR = 1.82, p < 0.001). UE was not associated with a worse five-year OS (RR = 0.90, p = 0.16), higher amputation rate (RR = 0.77, p = 0.134), or a worse plastic reconstruction surgery rate (RR = 1.25, p = 0.244). CONCLUSIONS Unplanned excision of Soft Tissue Sarcomas and the presence of disease in tumor bed after one were associated with worse five-year LRFS. Tumor bed excision should remain the standard approach, with special consideration to the presence of residual disease.
Collapse
Affiliation(s)
- Felipe Larios
- Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima 15102, Peru; (F.L.); (K.R.-A.)
| | - Marcos R. Gonzalez
- Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA;
| | - Kim Ruiz-Arellanos
- Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima 15102, Peru; (F.L.); (K.R.-A.)
| | | | - Juan Pretell-Mazzini
- Miami Cancer Institute, Division of Orthopedic Oncology, Baptist Health System South Florida, Plantation, FL 33324, USA
| |
Collapse
|
5
|
Schärer M, Heesen P, Bode-Lesniewska B, Studer G, Fuchs B. Benchmarking Time-to-Treatment Initiation in Sarcoma Care Using Real-World-Time Data. Cancers (Basel) 2023; 15:5849. [PMID: 38136394 PMCID: PMC10741448 DOI: 10.3390/cancers15245849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 12/03/2023] [Accepted: 12/13/2023] [Indexed: 12/24/2023] Open
Abstract
Benchmarking is a fundamental tool for enhancing quality within a patient-centered healthcare framework. This study presents an analysis of time-to-treatment initiation (TTI) for sarcoma patients, utilizing a database encompassing 266 cases from the Swiss Sarcoma Network. Our findings indicate a median TTI of 30 days across the cohort, with bone sarcomas and deep soft tissue sarcomas demonstrating a shorter median TTI of 28 days, followed by superficial soft tissue sarcomas at 42 days. The data reveal that the use of real-world-time data (RWTD) may account for a longer TTI observed, as it offers more comprehensive capture of patient journeys, unlike conventional datasets. Notably, variability in TTI was observed between different treatment institutions, which underscores the need for standardized processes across centers. We advocate for a selective referral system to specialized centers to prevent capacity overload and ensure timely treatment initiation. Our analysis also identified significant delays in TTI for unplanned 'whoops'-resections, highlighting the importance of early specialist referral in optimizing treatment timelines. This study emphasizes the potential benefits of a streamlined, data-informed approach to sarcoma care. However, further research is required to establish the direct impact of integrated care models on TTI and patient outcomes in the context of sarcoma treatment.
Collapse
Affiliation(s)
- Markus Schärer
- Sarcoma Service, Department of Orthopaedics and Trauma, University Teaching Hospital LUKS, 6000 Lucerne, Switzerland;
- Health Sciences and Medical Faculty, University of Lucerne, 6001 Lucerne, Switzerland
- Sarcoma Service, Department of Orthopaedics and Trauma, Kantonsspital Winterthur, 8400 Winterthur, Switzerland
| | - Philip Heesen
- Sarcoma Service, University Hospital USZ, University of Zurich, 8000 Zurich, Switzerland;
| | | | - Gabriela Studer
- Health Sciences and Medical Faculty, University of Lucerne, 6001 Lucerne, Switzerland
| | - Bruno Fuchs
- Sarcoma Service, Department of Orthopaedics and Trauma, University Teaching Hospital LUKS, 6000 Lucerne, Switzerland;
- Health Sciences and Medical Faculty, University of Lucerne, 6001 Lucerne, Switzerland
- Sarcoma Service, University Hospital USZ, University of Zurich, 8000 Zurich, Switzerland;
- Pathologie Institut Enge, University of Zurich, 8000 Zurich, Switzerland
| |
Collapse
|
6
|
Yang C, Reissfelder C, Jakob J. [Unplanned excision of extremity and superficial trunk soft tissue sarcomas]. CHIRURGIE (HEIDELBERG, GERMANY) 2023; 94:881-882. [PMID: 37707521 DOI: 10.1007/s00104-023-01962-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 08/07/2023] [Indexed: 09/15/2023]
Affiliation(s)
- Cui Yang
- Chirurgische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland
| | - Christoph Reissfelder
- Chirurgische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland
| | - Jens Jakob
- Chirurgische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
| |
Collapse
|
7
|
Wang EHM, Araneta KTS, Gaston CLL, Rubio DAT, de Dios AMV, Cañal JPA, Goleta-Dy AN, Alcasabas APA, Odoño EG, Atun JML, Fernando GY, Dimayuga CCD, Quintos AJD. Unplanned Excision of Soft Tissue Sarcomas of the Extremities in a Low-to-Middle-Income Country. Ann Surg Oncol 2023; 30:3681-3689. [PMID: 36800129 PMCID: PMC9936942 DOI: 10.1245/s10434-023-13188-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 01/14/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND Outcomes of unplanned excisions of extremity soft tissue sarcomas (STSE) range from poor to even superior compared with planned excisions in developed countries. However, little is known regarding outcomes in low-to-middle-income countries. This study aimed to determine whether definitively treated STSE patients with a previous unplanned excision have poorer oncologic outcomes compared with those with planned excisions. PATIENTS AND METHODS Using the database of a single sarcoma practice, we reviewed 148 patients with STSE managed with definitive surgery-78 with previous unplanned excisions (UE) and 70 with planned excisions (PE). RESULTS Median follow-up was 4.4 years. UE patients had more surgeries overall and plastic reconstructions (P < 0.001). On multivariate analysis, overall survival (OS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were not worse among UE patients compared with PE patients. Negative predictors for LRFS were high tumor grade (P = 0.031) and an R1 surgical margin (P < 0.001). High grade (P <0.001), local recurrence (P = 0.001), and planned excisions (P = 0.009) predicted poorer DMFS, while age over 65 years (P = 0.011) and distant metastasis predicted poorer OS (P < 0.001). CONCLUSIONS We recommend systematic re-excision for patients with unplanned excisions. Our study shows that STSE patients with UE, when subjected to re-excision with appropriate surgical margins, can achieve oncologic results similar to those for PE patients. However, there is an associated increased number of surgeries and plastic reconstruction for UE patients. This underscores the need, especially in a resource-limited setting, for education and collaborative policies to raise awareness about STSE among patients and physicians.
Collapse
Affiliation(s)
- Edward H. M. Wang
- Department of Orthopedics, Section of Tumor Orthopedics, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | | | - Czar Louie L. Gaston
- Department of Orthopedics, Section of Tumor Orthopedics, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Donnel Alexis T. Rubio
- Department of Orthopedics, Section of Tumor Orthopedics, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Ariel M. Vergel de Dios
- Department of Pathology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Johanna Patricia A. Cañal
- Department of Radiology, Section of Radiation Oncology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Amy N. Goleta-Dy
- Department of Pediatrics, Section of Hematologic Oncology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Ana Patricia A. Alcasabas
- Department of Pediatrics, Section of Hematologic Oncology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Eugene G. Odoño
- Department of Pathology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Jenny Maureen L. Atun
- Department of Pathology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Gracieux Y. Fernando
- Department of Internal Medicine, Section of Medical Oncology, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Cesar Cipriano D. Dimayuga
- Department of Orthopedics, Section of Tumor Orthopedics, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - Albert Jerome D. Quintos
- Department of Orthopedics, Section of Tumor Orthopedics, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
| |
Collapse
|
8
|
Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, Wardelmann E, Hofer S. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. Eur J Cancer 2023; 180:158-179. [PMID: 36599184 DOI: 10.1016/j.ejca.2022.11.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 11/04/2022] [Indexed: 11/17/2022]
Abstract
BACKGROUND Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence. METHODS During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022. RESULTS Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (≥95%) items were identified by the experts, as well as 30 items with a ≥75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus. CONCLUSIONS In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS.
Collapse
Affiliation(s)
- Christian Rothermundt
- Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
| | - Dimosthenis Andreou
- Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria
| | - Jean-Yves Blay
- Department of Medicine, Léon Bérard Center, Lyon, France
| | - Thomas Brodowicz
- Department of Medical Oncology, General Hospital - Medical University of Vienna, Vienna, Austria
| | - Ingrid M E Desar
- Department of Medical Oncology, Radboud University Medical Center Nijmegen, the Netherlands
| | - Palma Dileo
- London Sarcoma Service, Department of Oncology, University College Hospital London, United Kingdom
| | - Hans Gelderblom
- Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Rick Haas
- Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and the Leiden University Medical Center, Leiden, the Netherlands
| | - Jens Jakob
- Sarcoma Unit, Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
| | - Robin L Jones
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
| | - Ian Judson
- The Institute of Cancer Research, London, United Kingdom
| | - Wolfgang G Kunz
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | | | - Lars H Lindner
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - Christina Messiou
- Department of Radiology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
| | - Aisha B Miah
- Department of Radiotherapy, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
| | - Peter Reichardt
- Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany
| | - Joanna Szkandera
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | | | - Winan J van Houdt
- Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Eva Wardelmann
- Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany
| | - Silvia Hofer
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | | |
Collapse
|
9
|
Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. Ann Surg Oncol 2023; 30:480-489. [PMID: 36085392 DOI: 10.1245/s10434-022-12359-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 07/11/2022] [Indexed: 12/13/2022]
Abstract
BACKGROUND Patients with unplanned excision (UPE) of trunk and extremity soft tissue sarcoma (STS) present a significant management challenge for sarcoma specialists. Oncologic re-resection has been considered standard practice after UPE with positive or uncertain margins. A strategy of active surveillance or "watch and wait" has been suggested as a safe alternative to routine re-excision. In this context, the current study sought to evaluate short-term outcomes and morbidity after re-resection to better understand the risks and benefits of this treatment strategy. METHODS A retrospective, single-institution study reviewed patients undergoing oncologic re-resection after UPE of an STS during a 5-year period (2015-2020), excluding those with evidence of gross residual disease. Short-term clinical outcomes were evaluated together with final pathologic findings. RESULTS The review identified 67 patients undergoing re-resection after UPE of an STS. Of these 67 patients, 45 (67%) were treated with a combination of external beam radiation therapy (EBRT) and surgery. Plastic surgery was involved for reconstruction in 49 cases (73%). The rate of wound complications after re-resection was 45 % (n = 30), with 15 % (n = 10) of the patients experiencing a major wound complication. Radiation therapy and plastic surgery involvement were independently associated with wound complications. Notably, 45 patients (67%) had no evidence of residual disease in the re-resection specimen, whereas 13 patients (19 %) had microscopic disease, and 9 patients (13%) had indeterminate pathology. CONCLUSION Given the morbidity of re-resection and limited identification of residual disease, treatment plans and discussions with patients should outline the expected pathologic findings and morbidity of surgery.
Collapse
Affiliation(s)
- Raymond S Traweek
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Allison N Martin
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Nikita F Rajkot
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - B Ashleigh Guadagnolo
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Andrew J Bishop
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Alexander J Lazar
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Emily Z Keung
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Keila E Torres
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kelly K Hunt
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Barry W Feig
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Christina L Roland
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Christopher P Scally
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
| |
Collapse
|
10
|
Traweek RS, Roland CL, Scally CP. ASO Author Reflections: Management of Patients with Soft Tissue Sarcoma Following Unplanned Excision. Ann Surg Oncol 2023; 30:490-491. [PMID: 36076129 DOI: 10.1245/s10434-022-12444-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 08/09/2022] [Indexed: 12/13/2022]
Affiliation(s)
- Raymond S Traweek
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christina L Roland
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher P Scally
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
11
|
Gouin F, Stoeckle E, Honoré C, Ropars M, Jafari M, Mattei JC, Rochwerger A, Carrere S, Waast D, Ferron G, Machiavello JC, Anract P, Marchal F, Sirveaux F, Marco O, Guiramand J, Paquette B, Di Marco A, Causeret S, Guilloit JM, Soibinet P, Tzanis D, Gimbergues P, Fiorenza F, Dujardin F, Le Nail LR, Ruzic JC, Chemin-Airiau C, Morelle M, Meeus P, Karanian M, Le Loarer F, Vaz G, Blay JY. Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis. BMC Cancer 2022; 22:1034. [PMID: 36192725 PMCID: PMC9531489 DOI: 10.1186/s12885-022-10121-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 09/09/2022] [Indexed: 12/02/2022] Open
Abstract
Background This French nationwide NETSARC exhaustive prospective cohort aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS) with positive microscopic margins (R1) after initial resection performed outside of a reference center. Methods Eligible patients had experienced STS surgery outside a reference center from 2010 to 2017, and had R1 margins after initial surgery. Characteristics and treatment comparisons used chi-square for categorical variables and Kruskall-Wallis test for continuous data. Survival distributions were compared in patients reexcised (RE) or not (No-RE) using a log-rank test. A Cox proportional hazard model was used for subgroup analysis. Results A total of 1,284 patients had experienced initial STS surgery outside NETSARC with R1 margins, including 1,029 patients with second operation documented. Among the latter, 698 patients experienced re-excision, and 331 were not re-excised. Characteristics were significantly different regarding patient age, tumor site, tumor size, tumor depth, and histotype in the population of patients re-excised (RE) or not (No-RE). The study identified RE as an independent favorable factor for OS (HR 0.36, 95%CI 0.23–0.56, p<0.0001), for LRFS (HR 0.45, 95%CI 0.36–0.56, p<0.0001), and for RFS (HR 0.35, 95%CI 0.26–0.46, p<0.0001). Conclusion This large nationwide series shows that RE improved overall survival in patients with STS of extremities and trunk wall, with prior R1 resection performed outside of a reference center. RE as part of adjuvant care should be systematically considered. Level of evidence II Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-10121-5.
Collapse
Affiliation(s)
| | | | - Charles Honoré
- Surgery department, Gustave Roussy Cancer Campus, Villejuif, France
| | - Mickael Ropars
- Orthopedic surgery department, CHU de Rennes, Rennes, France
| | - Mehrdad Jafari
- General and digestive oncologic surgery, Centre Oscar Lambret, Lille, France
| | - Jean Camille Mattei
- Ramsay Santé, Hôpital Privé Clairval, Marseille, France.,Aix Marseille University, Marseille, France.,INSERM, MMG, Marseille, France.,Orthopedic and traumatologic surgery department, Hôpital Nord, Marseille, France.,Hopital de la Conception, APHM, Marseille, France
| | - Alexandre Rochwerger
- INSERM, MMG, Marseille, France.,Hopital de la Conception, APHM, Marseille, France
| | - Sébastien Carrere
- Surgery department, Institut de recherche en cancérologie, Montpellier, France
| | - Denis Waast
- Orthopedic and traumatologic surgery clinic, CHU, Nantes, France
| | | | | | - Philippe Anract
- Orthopedic surgery department, Hôpital Cochin, AP-HP, Paris, France
| | - Frédéric Marchal
- Surgery department, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS, CRAN, UMR 7039, Vandoeuvre-les-Nancy, France
| | | | - Oren Marco
- Reconstructive et esthetic plastic surgery, Hôpital Saint Louis, Paris, France
| | | | - Brice Paquette
- Department of Digestive Surgery, Jean Minjoz University Hospital, Besançon, France
| | - Antonio Di Marco
- Orthopedic surgery department, CHU de Strasbourg, Strasbourg, France
| | - Sylvain Causeret
- Surgery department, Centre George-François Leclerc, Dijon, France
| | - Jean-Marc Guilloit
- Visceral et digestive surgery department, Centre François Baclesse, Caen, France
| | | | - Dimitri Tzanis
- Surgery department, Institut Curie, PSL university, Paris, France
| | | | - Fabrice Fiorenza
- Orthopedic and traumatology surgery department, CHU Limoges, Limoges, France
| | - Franck Dujardin
- Medical Oncology and Surgical Oncology department, Centre Henri Becquerel, Rouen, France
| | - Louis R Le Nail
- Onco-orthopedic surgery department, Hôpital Trousseau, CHRU de Tours, Tours, France
| | | | | | - Magali Morelle
- Clinical research and innovation department, Centre Léon Bérard, Lyon, France
| | - Pierre Meeus
- Surgery department, Centre Léon Bérard, Lyon, France
| | - Marie Karanian
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - François Le Loarer
- Anatomo-pathology surgery department, Institut Bergonié, Bordeaux, France
| | - Gualter Vaz
- Surgery department, Centre Léon Bérard, Lyon, France
| | - Jean-Yves Blay
- Medical oncology Centre Léon Bérard, Lyon, France.,University Claude Bernard Lyon I, Lyon, France.,Headquarters, Unicancer, Paris, France
| | | |
Collapse
|
12
|
Acem I, van de Sande MAJ. Prediction tools for the personalized management of soft-tissue sarcomas of the extremity. Bone Joint J 2022; 104-B:1011-1016. [PMID: 36047022 PMCID: PMC9987162 DOI: 10.1302/0301-620x.104b9.bjj-2022-0647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Prediction tools are instruments which are commonly used to estimate the prognosis in oncology and facilitate clinical decision-making in a more personalized manner. Their popularity is shown by the increasing numbers of prediction tools, which have been described in the medical literature. Many of these tools have been shown to be useful in the field of soft-tissue sarcoma of the extremities (eSTS). In this annotation, we aim to provide an overview of the available prediction tools for eSTS, provide an approach for clinicians to evaluate the performance and usefulness of the available tools for their own patients, and discuss their possible applications in the management of patients with an eSTS.Cite this article: Bone Joint J 2022;104-B(9):1011-1016.
Collapse
Affiliation(s)
- Ibtissam Acem
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.,Department of Orthopaedic Oncology, Leiden University Medical Centre, Leiden, the Netherlands
| | | |
Collapse
|
13
|
Radaelli S, Pasquali S, Colombo C, Callegaro D, Sanfilippo R, Stacchiotti S, Provenzano S, Sangalli C, Morosi C, Barisella M, Miceli R, Fiore M, Gronchi A. Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. Eur J Surg Oncol 2022; 48:1723-1729. [DOI: 10.1016/j.ejso.2022.01.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 12/28/2021] [Accepted: 01/03/2022] [Indexed: 12/21/2022] Open
|
14
|
Tirotta F, Sayyed R, Jones RL, Hayes AJ. Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Expert Rev Anticancer Ther 2021; 22:83-95. [PMID: 34822313 DOI: 10.1080/14737140.2022.2011723] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
INTRODUCTION Local recurrence (LR) is one of the main pitfalls in surgery for extremities soft tissue sarcoma (eSTS). Achieving clear histopathological margins is the most important factor to reduce the risk of LR, but the ability to do so depends on not only surgical technique but also the interplay between tumor biology, anatomical location and surgical approach. The balance between postoperative morbidity and oncological benefits in reducing the risk of LR needs to be considered. AREAS COVERED This review will cover which etiological factors for the development of eSTS lead to an increased risk of LR and discuss histological subtypes that have a high risk of LR and which surgical and neoadjuvant therapeutic strategies can minimize the risk of LR. EXPERT OPINION The traditional view that surgical radicality always results in low rates of LR, while marginality alone always leads to high rates of relapse, is outdated. In the modern era of surgical oncology, limb salvage and high-level function after resectional surgery are the key surgical goals. The best results are achieved by combining effective neoadjuvant treatments with planned bespoke oncological operations that consider the biological and anatomical factors of each individual sarcoma.
Collapse
Affiliation(s)
- Fabio Tirotta
- Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Raza Sayyed
- Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Robin L Jones
- Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Andrew J Hayes
- Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
15
|
Danieli M, Gronchi A. ASO Author Reflections: Reexcision after Macroscopically Complete Unplanned Excision in Extremity and Trunk Wall Soft Tissue Sarcoma: Is Less More? Ann Surg Oncol 2021; 28:4718-4719. [PMID: 33512675 DOI: 10.1245/s10434-021-09632-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 01/12/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Maria Danieli
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Alessandro Gronchi
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|